Cadila Healthcare receives warning letter from US FDA

By: |
Updated: December 31, 2015 12:31 PM

The letters were received for its two facilities in Gujarat Cadila Healthcare has received a warning letter from the US Food and Drug Administration (US FDA) for its two facilities in Gujarat. “The company has received a warning letter issued by US FDA relating to its Moraiya formulation facility and Ahmedabad API facility (Zyfine) in […]

The letters were received for its two facilities in Gujarat

Cadila Healthcare has received a warning letter from the US Food and Drug Administration (US FDA) for its two facilities in Gujarat.

“The company has received a warning letter issued by US FDA relating to its Moraiya formulation facility and Ahmedabad API facility (Zyfine) in Gujarat,” Cadila Healthcare said in a BSE filing.

“The company is working hard to ensure that the commitments made to US FDA are fully completed. The company will continue to take all necessary steps to ensure that the US health regulator is fully satisfied with our remediation of the above facilities,” it added.

Cadila Healthcare said there are no products in the US market which use Active Pharmaceutical Ingredient (API) of Zyfine facility.

“We will respond to US FDA to address the observations within the statutory time permitted in the letter. We are committed to resolve all the issues and revamp our quality systems and processes as the top most priority,” the company added.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.